Stock Chart Alerts
Written by a Wall Street veteran with over 120,000 subscribers, this newsletter provides in-depth analysis and commentary on the latest market trends and stock picks. This is a Substack Bestselling publication.
- Top in Finance
- #115
- Subscribers
- 59K
- Paid subscribers
- 10+ paid
- Followers
- 60K
- Paid plan
- $59.99/mo
- Recommends
- 0
- Podcast
- Yes
rounded by Substack
other newsletters
Most-mentioned tickers
Symbols named in the headline of a post from the last 30 days, most-covered first. The number is how many of those posts mentioned it.
Read from 9 post headlines in the last 30 days. A newsletter that names a company only in the body of a post will not appear here, and a mention is not a recommendation — it only means the symbol came up.
Growth history
Subscribers (thousands, nightly)
59K on Sep 10, 2026 → 59K on Sep 30, 2026
Followers (thousands, nightly)
Rank in Substack’s finance leaderboard: #115 today · #116 a week ago
Stats worth sharing
Tracked since Sep 10, 2026 — 21 daily snapshots so far. The card below is built from what we track and refreshes nightly.
- Percentile
- Top 22%
- Best rank seen
- #98
- Rank, 7 days
- +1 place
- Followers added
- −225
- Posts
- 9
- Reactions per post
- 15
- Reactions tracked
- 278
- Tickers covered
- 4
of 525 ranked finance newsletters
on Sep 26, 2026
since tracking began
last 30 days
average, recent posts
across 19 posts
in tracked posts
Most-reacted post we have seen: Copper Just Hit an All-Time High. Here Are the 5 Copper Stocks We're Watching Right Now. — 30 reactions on Aug 28, 2026.
Recent posts
- $DNA +85% Since Our Alert. This Is Why You Read Stock Chart Alerts.
- $DNA Rips 12% Today. +47% Since We Alerted It.
Hey traders and VIP members, Sir Chartist here… and what a morning. Ginkgo Bioworks (NYSE: DNA) is up 12% today and just printed $9.63. When we put this name in front of you, it was $6.56 and Wall Street had it rated Sell. Nobody was talking about it. Now it’s up 47% from our alert , and every financial outlet is suddenly discovering the “autonomous lab” story we laid out for you weeks ago. That’s not luck. That’s the work. HOW WE GOT HERE We told you Ginkgo had quietly transformed from an overhyped science project into a company that sells its robots and software as a product. We told you…
- CRDL: Digging Deeper — Why the MAVERIC Expansion Could Be the Smartest Move Cardiol Has Made
CRDL: Digging Deeper — Why the MAVERIC Expansion Could Be the Smartest Move Cardiol Has Made NASDAQ: CRDL | Cardiol Therapeutics Inc. | Sponsored Follow-Up Alert Catching You Up In our last alert, we covered Cardiol Therapeutics’ September 23 announcement: its pivotal Phase III MAVERIC trial in recurrent pericarditis hit its 110-patient enrollment target ahead of schedule , and the steering committee recommended expanding enrollment to up to 150 patients after a blinded review showed fewer-than-expected recurrences. Today we’re going one level deeper — because the details behind this decision…
- Wall Street Doubles Down: H.C. Wainwright Reiterates Buy on CRDL, Holds $9 Target
Wall Street Doubles Down: H.C. Wainwright Reiterates Buy on CRDL, Holds $9 Target NASDAQ: CRDL | Cardiol Therapeutics Inc. | Sponsored Flash Alert — September 23, 2026 Just In H.C. Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Cardiol Therapeutics (NASDAQ: CRDL) , maintaining a $9 price target (Currently at 1.86) The timing is not subtle. This reiteration lands the same day Cardiol announced its pivotal Phase III MAVERIC trial hit its enrollment target ahead of schedule and expanded to up to 150 patients. When the covering analyst sits down with management and comes…
- CRDL Hits Phase III Enrollment Target Early — and Expands the Pivotal Trial
CRDL Hits Phase III Enrollment Target Early — and Expands the Pivotal Trial NASDAQ: CRDL | Cardiol Therapeutics Inc. | September 23, 2026| Sponsored Content The News (Released Today) This morning, Cardiol Therapeutics (NASDAQ: CRDL) announced that its pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis has achieved its original 110-patient enrollment target ahead of schedule — beating the company’s own end-of-September guidance. But the bigger story: the MAVERIC Steering Committee has recommended expanding enrollment to up to 150 patients . The reason? A blinded review…
- $DNA +46%: A Win for This Community
Hey everyone, Sir Chartist here. Days like today are why we do this. First…We have a ALERT TOMORROW PRE MARKET ! As you know we just called DNA before it went bananas! And….tomorrow our alert will be hours before the market opens so CHECK YOUR SUBSTACK APP ! Get more from Sir Chartist in the Substack app Available for iOS and Android Get the app When we first alerted Ginkgo Bioworks (NYSE: DNA) at $6.56, the Street had it rated Sell, the headlines were all about cash burn, and the only people paying attention were the ones doing the actual reading. Today the stock touched $9.60. That’s a gain…
- $DNA Pays Off +22%. Now, the $CRDL Deep Dive.
Hey everyone, Sir Chartist here. Two quick things today: a win to acknowledge, and then the deep dive a lot of you have been asking for. First, the win. We alerted Ginkgo Bioworks (NYSE: DNA) at $6.56. Today the stock traded above $8, a move of roughly 22% . If you did your own work on that one and acted on it, that’s your win, not mine — but I’ll admit it feels good to see the thesis play out. The ARPA-H contract we broke down last week seems to be getting the market’s attention after all. Now to the name that remains our main focus: Cardiol Therapeutics (NASDAQ: CRDL). Stock Chart Alerts is…
- $DNA Just Landed Government Money for Its Robot Labs
Welcome back to Stock Alerts Pro. Fresh news on a name we’ve been following. This morning, Ginkgo Bioworks (NYSE: DNA) announced it has secured up to $17.5 million in funding under ARPA-H’s GIVE program — Genetic Medicines and Individualized Manufacturing for Everyone — to develop autonomous manufacturing systems for individualized RNA medicines. THE NEWS…
- We Called $DNA First. Now James Altucher Is Talking.
Welcome back to Stock Alerts Pro. On August 17th we flagged Ginkgo Bioworks (NYSE: ) at $6.60. The stock touched $7.50 yesterday. Congratulations to everyone who read that issue and did their own work — you were early. Now a much bigger name has picked up the story. WHAT ALTUCHER SAID James Altucher posted a long idea on DNA this week: “Ginkgo’s robot lab…
- Copper Just Hit an All-Time High. Here Are the 5 Copper Stocks We're Watching Right Now.
Let me get straight to the point, because that’s what you subscribe for. On August 25th, copper futures on the COMEX hit an all-time record of roughly $6.73 per pound (about $14,800 per tonne). On the London Metal Exchange, three-month copper traded above $14,300 per tonne intraday — territory the metal had never seen before this year. Copper first broke…
- From $1.06 to $2.20: The CRDL Run Continues (Plus DNA Breaks Out)
Welcome back to Stock Alerts Pro. Two names we’ve covered recently are moving, so we’re sending a quick update on both. CARDIOL THERAPEUTICS (NASDAQ: CRDL) — $2.20, UP 10% TODAY
- CRDL Update: From $1.06 to $2.00
Welcome back to Stock Alerts Pro. When we covered Cardiol Therapeutics (NASDAQ: CRDL) on July 14, 2026, the stock was trading around $1.06. Today it hit $2.00, a new 52-week high and a gain of roughly 89% since that issue. Congratulations to everyone who read that breakdown and did their own homework on the name. WHAT HAPPENED Three things moved the stock:
← All trending finance newsletters
Data: Substack public leaderboards and publication archives, refreshed nightly, plus public beehiiv sitemaps and recommendation pages, refreshed weekly. Source for this page: Stock Chart Alerts. Subscriber counts are Substack’s own rounded public figures, so week-on-week changes move in steps. beehiiv audience sizes are self-reported by the publisher and are not verified. Last snapshot: Sep 30, 2026.